Article Text

Download PDFPDF

158 Non-epithelial ovarian tumors: A single institute retrospective study
Free
  1. I de Sá1,
  2. S Raposo2,
  3. R Sousa2 and
  4. L Sá2
  1. 1Centro Hospitalar de Trás-os-Montes e Alto Douro, Portugal
  2. 2Instituto Português Oncologia Francisco Gentil, Portugal

Abstract

Introduction Non-epithelial ovarian tumors (NEOT) account for 10% of ovarian cancers. They occur in all age groups and include diverse tumors of germ cell origin, sex cord-stromal cell origin, as well as extremely rare types of ovarian cancer. The etiology and molecular origins of each sub-group remain poorly understood. Our aim is to determine the clinical, epidemiologic and histological features of the NEOT.

Methods A retrospective coorte study involving 33 patients diagnosed with NEOT and treated at IPO-Coimbra between 2011–2015. Patients ‘data were obtained from hospital records.

Results The average age was 56 years. 42.4% of the patients were pre menopausal. We diagnosed 11 germ cell tumors (9 mature cystic teratomas, 1 mature teratoma and 1 immature teratoma), 21 sex cord-stromal tumors (16 ovarian fibromas/thecomas, 3 adult granulosa cell tumors, 1 juvenile granulosa cell tumor and 1 Sertoli-Leydig cell tumor) and 1 small cell carcinoma hypercalcaemic type tumor. All patients had surgery as a primary treatment; in 18.2% of the cases was performed a conservative surgery. Only 9.1% of patients were diagnosed in a stage > IA (FIGO). 2 patients were subjected to adjuvant chemotherapy (Sertoli-Leydig cell tumor and immature teratoma). After a mean follow up of 2.2 years, we reported 3 cases of relapse. 3 patients died between 2011–2015, but only one due the disease. The overall survival at 5 years was 97%.

Conclusions Our study reveals that the overall prognosis of NEOT is good. Relapse cases were mainly related to FIGO stage and more rare histologic type of tumor.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.